MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.41
-0.17
-1.98%
Pre Market: 8.05 -0.36 -4.28% 06:59 03/04 EST
OPEN
8.56
PREV CLOSE
8.58
HIGH
8.73
LOW
8.11
VOLUME
10
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
1.260
MARKET CAP
1.65B
P/E (TTM)
-8.6612
1D
5D
1M
3M
1Y
5Y
--Analyst Actions: B. Riley Raises Precigen's Price Target to $14 from $10, Keeps Buy Rating
MT Newswires · 2d ago
DJ Precigen, Inc. CEO Helen Sabzevari on Q4 2020 Results -- Earnings Call Transcript >PGEN
Dow Jones · 2d ago
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Zacks.com · 2d ago
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Zacks.com · 2d ago
BRIEF-Precigen Reports Q4 Revenue Of $19.3 Mln
reuters.com · 2d ago
Precigen 4Q Rev $19.3M >PGEN
Precigen 4Q Rev $19.3M >PGEN
Dow Jones · 2d ago
Precigen 4Q Loss/Shr 23c >PGEN
Precigen 4Q Loss/Shr 23c >PGEN
Dow Jones · 2d ago
Precigen 4Q Loss $41.7M >PGEN
Precigen 4Q Loss $41.7M >PGEN
Dow Jones · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PGEN. Analyze the recent business situations of Precigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PGEN stock price target is 11.83 with a high estimate of 14.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 283
Institutional Holdings: 123.50M
% Owned: 63.02%
Shares Outstanding: 195.95M
TypeInstitutionsShares
Increased
34
3.23M
New
46
-134.45K
Decreased
53
5.69M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer
Helen Sabzevari
Chief Financial Officer/Primary Contact
Rick Sterling
Senior Vice President
Jeffrey Perez
Executive Officer
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
Declaration Date
Dividend Per Share
Ex-Div Date
06/08/2015
Dividend USD 0.162
06/09/2015
About PGEN
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.